source
- Incyte drops early-stage JAK2 inhibitor to prioritize next-generation pipelineIncyte announced it is terminating development of its early-stage oral JAK2 inhibitor, INCB160058, after a Phase 1 study in myeloproliferative neoplasms. The company said the decision reflects the…
- Novo Nordisk loses bid to dismiss lawsuit over CagriSema trial readoutU.S. District Judge Robert Kirsch in New Jersey refused to dismiss most of the securities lawsuit filed by investors after Novo Nordisk’s CagriSema readout. While the judge found the plaintiffs’ cl…